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Abstract: Hypertension is one of the most important and widespread risk factors for the 
 development of cardiovascular disease. Once, combination therapy was traditionally reserved 
as a third-line or fourth-line approach in the management of hypertension. However, several 
major intervention trials in high-risk patient populations have shown that an average of 2–4 
antihypertensive agents are required to achieve effective blood pressure control. Combination 
treatment should be considered as a first choice in patients at high cardiovascular risk and in 
individuals for whom blood pressure is markedly above the hypertension threshold (eg, more 
than 20 mmHg systolic or 10 mmHg diastolic), or when milder degrees of blood pressure eleva-
tion are associated with multiple risk factors, subclinical organ damage, diabetes, renal failure, 
or associated cardiovascular disease. A number of clinical trials have demonstrated that a fixed 
combination of lercanidipine and enalapril has better efficacy and tolerability than monotherapy 
with either agents. The fixed-dose formulation of lercanidipine–enalapril was well tolerated in all 
clinical trials, with an adverse event rate similar to that of the component drugs as monotherapy. 
The advantages of combination therapy include improved adherence to therapy and minimization 
of blood pressure variability. In addition, combining two antihypertensive agents with different 
mechanisms of action may provide greater protection against major cardiovascular events and 
the development of end-organ damage.
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Introduction
Hypertension is one of the most important and widespread cardiovascular risk  factors 
responsible for the development of cerebrovascular disorders, heart disease, and renal 
failure. Combination therapy was traditionally reserved as a third-line or fourth-line 
approach in the management of hypertension.1 However, several major intervention tri-
als in high-risk patient populations have shown that an average of 2–4 antihypertensive 
agents are required to achieve effective blood pressure control.2–8 The European Society 
of Hypertension guidelines9 comment on the possibility of starting antihypertensive 
treatment with a single drug at low dose or with combination therapy. In fact, the so-
called “responder rate” (systolic and diastolic blood pressure reduction $20 mmHg and 
10 mmHg, respectively) to any agent in monotherapy is approximately 50%,10 and the 
ability of any agent used alone to achieve target blood pressure values (,140/90 mmHg) 
does not exceed 20%–30% in the overall hypertensive population, except in subjects 
with grade 1 hypertension.11,12
In most trials, a combination of two or more drugs has been the most widely 
used treatment regimen to reduce blood pressure effectively. Combination therapy 
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has been found to be more effective in high-risk patients 
and diabetics, and whenever lower blood pressure targets 
are needed.13
An obvious disadvantage of initiating treatment with 
two drugs is the potential exposure of some patients to an 
unnecessary agent. However, the advantages seem to be 
overwhelming. In fact, by using a combination, both drugs 
can be given in lower dosage, thus minimizing the risk of side 
effects compared with full-dose monotherapy. Furthermore, 
fixed low-dose combinations are available, allowing two 
agents to be administered in a single tablet, both simplifying 
and optimizing treatment and compliance. The advantages 
of combination therapy are well documented, with increased 
antihypertensive efficacy as a result of the simultaneous 
inhibition of different mechanisms of action, with a lesser 
incidence of adverse events, because of the possible com-
pensatory responses and the lower doses used.14
Starting treatment with a two-drug combination therapy 
may allow blood pressure control to be achieved in a 
shorter time. This may be of critical importance in high-risk 
patients, because the VALUE (Valsartan Antihypertensive 
 Long-term Use Evaluation) trial demonstrated that in the first 
6 months of treatment, a greater blood pressure reduction 
(23.8/22.2 mmHg) obtained in amlodipine-treated versus 
valsartan-treated patients was accompanied by a difference 
in cardiovascular event rate in favor of the more effectively 
treated group.4,9
Combination treatment should be considered as the 
first choice in patients at high cardiovascular risk and in 
individuals for whom blood pressure is markedly above 
the hypertension threshold (eg, more than 20 mmHg 
systolic or 10 mmHg diastolic), or when milder degrees of 
blood pressure elevation are associated with multiple risk 
factors, subclinical organ damage, diabetes, renal failure, or 
associated cardiovascular disease.9
In all these conditions, the need to obtain a larger blood 
pressure reduction could not be satisfied by monotherapy 
alone, and often more than two drugs are needed. Guidelines 
recommend various two-drug combinations of different 
classes of antihypertensive agents based on data derived 
from controlled interventional trials, but 3–4 drugs may be 
required depending on the patient’s risk profile.
In clinical practice, numerous fixed-dose antihyperten-
sive combination regimens are widely available, ie, a beta-
blocker + hydrochlorothiazide, an angiotensin-converting 
enzyme inhibitor + hydrochlorothiazide, an angiotensin 
receptor blocker + hydrochlorothiazide, and a calcium chan-
nel blocker + angiotensin-converting enzyme inhibitor.15
Many studies have shown that newer antihypertensive 
agents, such as calcium channel blockers, angiotensin recep-
tor blockers, and angiotensin-converting enzyme inhibitors, 
provide additional benefits by reducing the incidence of 
cardiovascular events in patients with hypertension.4,16–18 
This review focuses on the fixed association of lercanidipine-
enalapril, pointing out the potential advantages of such a 
combination.
Lercanidipine
Calcium channel blockers are extensively used in clinical 
practice, and several randomized clinical trials have shown 
that calcium channel blockers are potent antihypertensive 
drugs with good tolerability both in the general hyperten-
sive population and in a wide range of patients, alone or in 
combination.14,19
Lercanidipine is a third-generation dihydropyridine 
calcium channel blocker which inhibits calcium entry through 
L-type calcium channels in smooth muscle cells of the car-
diovascular system, leading to peripheral vasodilatation20–22 
and so exerting its antihypertensive effect. It is a highly 
lipophilic drug and has a slower onset and longer duration 
of action than other dihydropyridines.23 Furthermore, the 
drug is highly vasoselective because of the high proportion 
of L-type calcium channels in arteries and has shown less 
in vitro and in vivo negative inotropic activity than some 
other dihydropyridines.20 Lercanidipine is a well tolerated 
drug with a low adverse event rate due to its long-lasting 
and vasoselective calcium entry blocking activity, and does 
not cause sympathetic activation and reflex tachycardia.24 
As a result, the overall adverse event rate is lower than that 
observed with other dihydropyridines.15 The efficacy of ler-
canidipine has been evaluated in both noncomparative and 
comparative studies with other calcium channel blockers 
and different antihypertensive drugs, showing comparable 
effects in all cases.25–30
Some studies have suggested that lercanidipine may 
have antiatherogenic effects beyond blood pressure 
reduction.21,31–33 Another reported benefit with lercanidipine 
is its renoprotective effect, which is related to its ability to 
induce both  afferent and efferent arteriolar vasodilatation.34,35 
Lercanidipine was also superior to ramipril in reducing albu-
min excretion in diabetic patients with microalbuminuria.35
In diabetic patients with hypertension, treatment with 
lercanidipine was able to decrease the glycosylated hemoglo-
bin level significantly, without negatively affecting glucose 
homeostasis, to enhance glucose tolerance, and to reduce fast-
ing blood glucose, with either neutral or favorable effects on 
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the lipid profile.22,36 Moreover, in diabetics with renal failure, 
lercanidipine had a good tolerability profile and a neutral effect 
on plasma lipids, with no impairment of renal function.37
In hypertensive patients with metabolic syndrome, 
lercanidipine appeared to have a better tolerability pro-
file and was associated with fewer vasodilatation-related 
adverse effects than other dihydropyridine calcium channel 
 blockers.15 Lercanidipine also reduces the signs and symp-
toms of ischemia, and improves heart function in patients 
with angina.38
Enalapril
The renin-angiotensin-aldosterone system plays a key role 
in regulating the homeostasis of fluids, electrolytes, and 
systemic vascular resistance. Overactivation of this system, 
especially through excessive production of its effector pep-
tide, angiotensin II, has been related to the genesis and devel-
opment of cardiovascular disease. Angiotensin-converting 
enzyme inhibitors are able to diminish plasma levels of 
angiotensin II by blocking the last step of its activation. This 
results in reduced vascular resistance, leading to a decrease 
in blood pressure values.14,39
Enalapril, one the most commonly prescribed angiotensin-
converting enzyme inhibitors in clinical practice in a number 
of European countries, is an orally administered prodrug that 
is hydrolyzed to the active metabolite, enalaprilat, which 
decreases plasma levels of angiotensin II by inhibiting the last 
step of its activation. The reduction of angiotensin II leads 
to peripheral vasodilatation and reduced vascular resistance, 
decreasing blood pressure values.21,39,40 Enalapril is a dose-
dependent antihypertensive drug, with its maximum effect 
occurring 6–8 hours after administration and a total duration 
of effect of 24–36 hours.40 Enalapril has been shown to be an 
effective antihypertensive agent, with positive effects on car-
diovascular risk factors, prevention of decline in renal func-
tion and other organ damage,41–44 like progression of intima 
media thickness in the carotid artery, an independent risk 
factor for cardiovascular and cerebrovascular disease.43 The 
cardiovascular protection associated with enalapril may be 
caused by potentiation of the effects of bradykinin.45  Further, 
in a randomized, double-blind, six-year trial in patients with 
diabetes and normoalbuminuria at baseline, enalapril reduced 
the development of microalbuminuria.42
Combination of enalapril–
lercanidipine
Because calcium channel blockers do not share the mode of 
action of renin-angiotensin-aldosterone system inhibitors, 
a combination of these agents should provide synergistic 
and complementary effects. Indeed, in patients with newly 
diagnosed stage 1 or 2 hypertension and in patients with inad-
equate blood pressure control after conventional low-dose 
monotherapy, combination therapy with a calcium channel 
blocker and an angiotensin-converting enzyme inhibitor may 
be particularly effective.46,47
Calcium channel blockers are potent vasodilators that 
induce reflex activation of the sympathetic system and 
the renin-angiotensin-aldosterone system. As a result, the 
use of an angiotensin-converting enzyme inhibitor may 
buffer this excessive activation. Moreover, since calcium 
channel blockers promote a negative sodium balance and 
an increase in angiotensin II levels, this may reinforce the 
antihypertensive effect of angiotensin-converting enzyme 
inhibition.48 On the other hand, the concomitance of both 
treatments may reduce the incidence of adverse events, in 
particular peripheral edema, due to an increase in intracap-
illary pressure as a consequence of selective diminution of 
precapillary arteriolar tone during blockade of calcium entry. 
Angiotensin-converting enzyme inhibitors reduce the lower 
extremity edema caused by calcium channel blockers, likely 
because of their ability to dilate both the arterial vascular bed 
and the venous capacitance vessels.49
In the SELECT (Systolic Evaluation of Lotrel Efficacy 
and Comparative Therapies) study, calcium channel blocker 
and angiotensin-converting enzyme inhibitor combination 
therapy with amlodipine and benazepril, respectively, was 
significantly more effective in reducing systolic blood pres-
sure and pulse pressure in patients with severe systolic hyper-
tension than either agent used alone.50 The combination of 
manidipine and delapril was also more effective in reducing 
blood pressure than either drug used alone, achieving blood 
pressure control in 73% of treated patients.51
Data from the trials show that calcium channel blocker 
therapy plus additional addon treatment is able to not only 
lower blood pressure, but also to improve patient outcomes. 
The HOT (Hypertension Optimal Treatment) trial showed 
that intensive lowering of blood pressure with calcium 
channel blocker-based therapy led to a low rate of cardio-
vascular events.52 In the Syst-Eur (Systolic Hypertension in 
Europe) and Syst-China (Systolic Hypertension in China) 
studies, nitrendipine plus a diuretic and an angiotensin-
converting enzyme inhibitor reduced the rate of cardiovas-
cular complications in elderly patients with isolated systolic 
hypertension.53,54
Data from the ASCOT study showed that treatment with 
amlodipine plus perindopril (an angiotensin- converting 
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enzyme inhibitor, added as required) versus atenolol 
(a beta-blocker) plus bendroflumethiazide (a diuretic, added 
as required) was more effective in reducing the risks of non-
fatal myocardial infarction or fatal coronary heart disease, 
fatal and nonfatal stroke, total cardiovascular events and 
procedures, all-cause mortality, and diabetes in patients 
with hypertension and at least three other cardiovascular risk 
factors.55 The ACCOMPLISH (Avoiding Cardiovascular 
Events through Combination Therapy in Patients Living 
with Systolic Hypertension) trial compared the effective-
ness of a maximally titrated, fixed-dose combination of 
benazepril (an angiotensin-converting enzyme inhibitor) 
and amlodipine (a dihydropyridine calcium channel blocker) 
with the combination of benazepril and hydrochlorothiazide 
in reducing cardiovascular morbidity and mortality. The 
trial was stopped early because of a 20% reduction in car-
diovascular risk recorded in the benazepril plus amlodipine 
group, so demonstrating that combination treatment with 
benazepril plus amlodipine reduces progression of chronic 
kidney disease and cardiovascular or all-cause mortality 
in high-risk hypertensive patients. Differences in blood 
pressure control throughout the study could not account 
for these findings.56
A number of clinical trials have demonstrated that the 
fixed combination of lercanidipine and enalapril has bet-
ter efficacy and tolerability than monotherapy with either 
agent57–60 (Table 1). In a trial performed in hypertensive 
patients nonresponsive to lercanidipine, after 12 weeks of 
treatment with fixed-combination lercanidipine–enalapril, 
a significantly greater proportion of patients had normal-
ized blood pressure compared with patients treated with 
lercanidipine as monotherapy (22% versus 12%, P = 0.012).59 
 Similarly, in another study carried out in hypertensive patients 
nonresponsive to enalapril, after 12 weeks of  treatment with 
this fixed combination, there was a trend towards better 
blood pressure control in the population treated with the 
fixed combination compared with enalapril as monotherapy 
(24% versus 17%).58
A randomized, double-blind, placebo-controlled study 
showed that reduction in blood pressure was greater in patients 
who received the lercanidipine–enalapril combination than 
in those assigned to receive either component as monothera-
py.6 In fact, all active treatments significantly reduced mean 
24-hour blood pressure and systolic blood pressure in the 
office compared with placebo, but the lercanidipine–enalapril 
combination was significantly more effective than the active 
components as monotherapy. Moreover, a higher proportion 
of patients treated with the lercanidipine–enalapril combina-
tion achieved their target blood pressure compared with those 
treated with lercanidipine or enalapril alone (45% versus 
18% versus 19%, respectively). In addition, lercanidipine 
was noninferior to hydrochlorothiazide as addon therapy in 
diabetic patients with hypertension who had not responded 
to enalapril alone.57
The fixed-dose formulation of lercanidipine–enalapril 
was well tolerated in all published clinical trials, with an 
adverse effect rate similar to that of the component drugs as 
monotherapy.57–60 Adverse effects were generally transient 
and of mild severity, and there were no reports of peripheral 
edema.57–60 Although infrequent, the most prevalent adverse 
events related to the use of the lercanidipine–enalapril com-
bination were cough, dizziness, and vertigo. Interestingly, no 
clinically significant differences in heart rate were observed 
between the treatment groups, and 24-hour heart rate 
remained stable on all treatments.60 The absence of negative 
effects of the combination on lipid and glucose metabolism 
appears to be an added advantage in the treatment of hyper-
tensive population.39
Table 1 Effect of fixed association of enalapril–lercanidipine on blood pressure control
Reference Patients, n Duration Intervention Outcome
Agrawal et al57 174 20 weeks Lercanidipine + enalapril 20 mg versus 
hydrochlorothiazide + enalapril 20 mg
SBP -9.6 versus -6.0 mmHg 
DBP -9.3 versus -7.4 mmHg
Recordati SpA58 338 12 weeks Enalapril 20 mg versus lercanidipine  
10 mg + enalapril 20 mg
SBP -6.7 versus -9.8 mmHg 
DBP -7.5 versus -9.2 mmHg
Recordati SpA59 337 12 weeks Lercanidipine 10 mg versus lercanidipine  
10 mg + enalapril 10 mg
SBP -2.3 versus -7.7 mmHg 
DBP -4.3 versus -7.1 mmHg
Puig et al60 75 4 months Lercanidipine10 mg versus enalapril 20 mg  
alone or in combination versus placebo
SBP -5 versus -5.9 versus  
16.9 mmHg, versus placebo
Rump61 8440 3 months Enalapril 10 mg + lercanidipine 10 mg or  
enalapril 10 mg + lercanidipine 20 mg
SBP -28.4 mmHg 
DBP -13.5 mmHg
Gil Guillén et al65 1562 6 months Lercanidipine + enalapril 20 mg alone  
or in combination
SBP -25.4 mmHg 
DBP -13.6 mmHg
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure.
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In an observational study which examined more than 
8000 patients, physician (general practitioners and spe-
cialist in internal medicine) subjective assessment of the 
lercanidipine–enalapril combination was positive, the 
efficacy of the fixed combination was assessed by 94% as 
“very good” to “good”. The physicians also assessed toler-
ability in 97% of the patients as “very good” or “good”, 
and assessed compliance as “very good” or “good” in 97% 
of patients.61
Conclusion
The main advantages of combination therapy include 
improved adherence to therapy62 and minimization of blood 
pressure variability. In addition, combining two antihyperten-
sive agents with different mechanisms of action may provide 
greater protection against major cardiovascular events and 
end-organ damage.9 Combinations of two drugs in a single 
tablet, usually at low doses, (but sometimes at both lower 
and higher doses), are now widely available. Although 
the fixed doses of the components in the combination limits 
the flexibility of upward and downward treatment strategies, 
fixed combinations reduce the number of tablets to be taken 
by the patient, and this has some advantage for compliance 
with treatment.62,63
Fixed-dose combinations can substitute extemporaneous 
combinations that have successfully controlled blood pres-
sure, but, when used at low doses, they can also be considered 
for first-step treatment.9 Guidelines recommend various two-
drug combinations of different classes of antihypertensive 
agents based on data derived from controlled interventional 
trials, but advise that 3–4 drugs may be required, depending 
on the patient’s risk profile.
In contrast, many studies have shown that newer anti-
hypertensive agents, including calcium channel blockers, 
angiotensin receptor blockers, and angiotensin-converting 
enzyme inhibitors, provide additional benefits by reduc-
ing the incidence of cardiovascular events in patients with 
hypertension.4,16–18 In addition, cases of new-onset diabetes 
are less common with newer antihypertensive agents than 
with older therapies, such as diuretics and beta-blockers.64 
Whether this is due to the deleterious effect of the older 
agents on glucose metabolism or to a positive effect of the 
newer agents remains to be clarified.19 A fixed combination 
of lercanidipine and enalapril has been shown to be effec-
tive in controlling calcium channel blocker levels and data 
about tolerability and patient compliance, indicating that 
this combination is a suitable, effective, and safe treatment 
for hypertension.
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